Clinics in Dermatology
Volume 25, Issue 2 , Pages 203-211 , March 2007

Cutaneous leishmaniasis

  • Mark S. Bailey, MRCP

      Affiliations

    • Army Medical Directorate, Camberley GU15 4NP, UK
    • Clinical Research Group, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
    • ,
  • Diana N.J. Lockwood, BSC, MD, FRCP

      Affiliations

    • Clinical Research Unit, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 0 207 927 2457; fax: +44 0 207 637 4314.

References 

  1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001;95:239–243
  2. Reyburn H, Rowland M, Mohsen M, Khan B, Davies C. The prolonged epidemic of anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: ‘bringing down the neighbourhood’. Trans R Soc Trop Med Hyg. 2003;97:170–176
  3. Bailey MS, Caddy AJ, McKinnon KA, et al. Zoonotic cutaneous leishmaniasis with local dissemination in Afghanistan. 2007 [in press].
  4. Harms G, Schönian G, Feldmeier H. Leishmaniasis in Germany. Emerg Infect Dis. 2003;9:872–875
  5. Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004;39:1674–1680
  6. Sanchez JL, Diniega BM, Small JW, et al. Epidemiologic investigation of an outbreak of cutaneous leishmaniasis in a defined geographic focus of transmission. Am J Trop Med Hyg. 1992;47:47–54
  7. Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S. Social impact of leishmaniasis, Afghanistan. Emerg Infect Dis. 2005;11:634–636
  8. Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, control trial. Clin Infect Dis. 2005;40:1148–1155
  9. Gradoni L, Gramiccia M. Leishmania infantum tropism: strain genotype or host immune status?. Parasitol Today. 1994;10:264–267
  10. Karunaweera ND, Pratlong F, Siriwardane HV, Ihalamulla RL, Dedet JP. Sri Lankan cutaneous leishmaniasis is caused by Leishmania donovani zymodeme MON-37. Trans R Soc Trop Med Hyg. 2003;97:380–381
  11. Noyes H, Chance M, Ponce C, Ponce E, Maingon R. Leishmania chagasi: genotypically similar parasites from Honduras cause both visceral and cutaneous leishmaniasis in humans. Exp Parasitol. 1997;85:264–273
  12. Zijlstra E, Musa A, Khalil E, El Hassan I, El-Hassan A. Post–kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3:87–98
  13. Mehregan DR, Mehregan AH, Mehregan DA. Histological diagnosis of cutaneous leishmaniasis. Clin Dermatol. 1999;17:297–304
  14. Ghersetich I, Menchini G, Teofoli P, Lotti T. Immune response to Leishmania infection in human skin. Clin Dermatol. 1999;17:333–338
  15. Kubba R, al-Gindan Y, el-Hassan AM, Omer AH, Kutty MK, Saeed MB. Dissemination in cutaneous leishmaniasis. II. Satellite papules and subcutaneous induration. Int J Dermatol. 1988;27:702–706
  16. Gaafar A, Fadl A, El Kadaro AY, et al. Sporotrichoid cutaneous leishmaniasis due to Leishmania major of different zymodemes in the Sudan and Saudi Arabia: a comparative study. Trans R Soc Trop Med Hyg. 1994;88:552–554
  17. Wortmann GW, Aronson NE, Miller RS, Blazes D, Oster CN. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis. 2000;31:199–201
  18. Al-Qurashi AR, Ghandour AM, Osman M, Al-Juma M. Dissemination in cutaneous leishmaniasis due to Leishmania major in different ethnic groups in Saudi Arabia. Int J Dermatol. 2000;39:832–836
  19. Turetz ML, Machado PR, Ko AI, et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis. 2002;186:1829–1834
  20. Schraner C, Hasse B, Hasse U, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis. 2005;40:e120–e124
  21. Silveira FT, Lainson R, Corbett CEP. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil—a review. Mem Inst Oswaldo Cruz. 2004;99:239–251
  22. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005;366:1561–1577
  23. Ahluwalia S, Lawn SD, Kanagalingam J, Grant H, Lockwood DNJ. Mucocutaneous leishmaniasis: an imported infection among travellers to central and South America. BMJ. 2004;329:842–844
  24. Lawn SD, Whetham J, Chodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM. 2004;97:781–788
  25. Couppie P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)–infected patients and non–HIV-infected patients in French Guiana. Br J Dermatol. 2004;151:1165–1171
  26. Pintado V, Lopez-Velez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect. 2001;7:291–300
  27. Motta AC, Arruda D, Souza CS, Foss NT. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol. 2003;42:703–706
  28. Gontijo CM, Pacheco RS, Orefice F, Lasmar E, Silva ES, Melo MN. Concurrent cutaneous, visceral and ocular leishmaniasis caused by Leishmania (Viannia) braziliensis in a kidney transplant patient. Mem Inst Oswaldo Cruz. 2002;97:751–753
  29. Ben Salah , Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg. 1995;53:162–166
  30. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for the treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg. 1995;53:648–651
  31. Dowlati Y. Cutaneous leishmaniasis: clinical aspects. Clin Dermatol. 1996;14:425–431
  32. Herwaldt B, Arana B, Navin T. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992;165:518–527
  33. Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg. 1994;88:334–339
  34. Siriwardena HV, Udagedara CU, Karunaweera ND. Clinical features, risk factors and efficacy of cryotherapy in cutaneous leishmaniasis in Sri Lanka. Ceylon Med J. 2003;48:10–12
  35. Ben Said M, Guerbouj S, Saghrouni F, Fathallah-Mili A, Guizani I. Occurrence of Leishmania infantum cutaneous leishmaniasis in central Tunisia. Trans R Soc Trop Med Hyg. 2006;100:521–526
  36. Ponce C, Ponce E, Morrison A, et al. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet. 1991;337:67–70
  37. Belli A, Garcia D, Palacios X, et al. Widespread atypical cutaneous Leishmaniasis caused by Leishmania (L.) chagasi in Nicaragua. Am J Trop Med Hyg. 1999;61:380–385
  38. Magill AJ. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am. 2005;19:241–266
  39. Bailey MS, Green AD, Ellis CJ, et al. Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J R Army Med Corps. 2005;151:73–80
  40. Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191–1199
  41. Ramirez JR, Agudelo S, Muskus C, et al. Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J Clin Microbiol. 2000;38:3768–3773
  42. Dar NR, Khurshid T. Comparison of skin smears and biopsy specimens for demonstration of Leishmania tropica bodies in cutaneous leishmaniasis. J Coll Physicians Surg Pak. 2005;15:765–767
  43. Laskay T, Miko TL, Negesse Y, Solbach W, Rollingoff M, Frommel D. Detection of cutaneous Leishmania infection in paraffin-embedded skin biopsies using the polymerase chain reaction. Trans R Soc Trop Med Hyg. 1995;89:273–275
  44. Bensoussan E, Nasereddin A, Jonas F, Schnur LF, Jaffe CL. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol. 2006;44:1435–1459
  45. Wortmann G, Hochberg L, Houng HH, et al. Rapid identification of Leishmania complexes by a real-time PCR assay. Am J Trop Med Hyg. 2005;73:999–1004
  46. Allahverdiyev AM, Uzun S, Bagirova M, Durdu M, Memisoglu HR. A sensitive new microculture method for diagnosis of cutaneous leishmaniasis. Am J Trop Med Hyg. 2004;70:294–297
  47. Chargui N, Bastien P, Kallel K, et al. Usefulness of PCR in the diagnosis of cutaneous leishmaniasis in Tunisia. Trans R Soc Trop Med Hyg. 2005;99:762–768
  48. Ihalamulla RL, Rajapaksa US, Karunaweera ND. Microculture for the isolation of Leishmania, modified to increase efficacy: a follow-up to a previous study. Ann Trop Med Parasitol. 2006;100:87–89
  49. Al-Jaser MH. Treatment trends of cutaneous leishmaniasis in Saudi Arabia. Saudi Med J. 2005;26:1220–1224
  50. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004;53:158–166
  51. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg. 2001;65:466–470
  52. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 2004;91:153–160
  53. Faghihi G, Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol. 2003;28:13–16
  54. Iraji F, Sadeghinia A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan. Iran Ann Trop Med Parasitol. 2005;99:3–9
  55. Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg. 2002;66:147–151
  56. Mujtaba G, Khalid M. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. Int J Dermatol. 1999;38:607–609
  57. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43:281–283
  58. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346:891–895
  59. Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World Cutaneous Leishmanasis in travellers treated with fluconazole: Drug effect or spontaneous evolution?. Am J Trop Med Hyg. 2007;76:48–52
  60. Willard RJ, Jeffcoat AM, Benson PM, Walsh DS. Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options. J Am Acad Dermatol. 2005;52:977–987
  61. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis and panamensis cutaneous leishmaniasis. Am J Med. 1990;89:147–155
  62. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992;165:528–534
  63. Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat. 2001;12:159–162
  64. Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole: randomised double-blind study. Arch Dermatol. 1996;132:784–786
  65. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol. 2005;19:80–83
  66. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis. 1993;16:417–425
  67. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004;38:1266–1272
  68. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992;46:296–306
  69. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis. 1998;27:1457–1464
  70. Wortmann G, Miller RS, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002;35:261–267
  71. Medicines and Healthcare products Regulatory Agency. Drug Alert – Pentostam Injection.MDR 47-03/66 dated 11 April 2006.
  72. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111–126
  73. Roussel M, Nacher M, Fremont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2006;100:307–314
  74. Seaton RA, Morrsion J, Man I, Watson J, Nathwani D. Out-patient parenteral antimicrobial therapy—a viable option for the management of cutaneous leishmaniasis. Q J Med. 1999;92:659–667
  75. Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg. 2006;100:264–269
  76. Lightburn E, Morand JJ, Meynard JB, et al. Management of American cutaneous leishmaniasis: outcome of 326 cases treated with high-dose pentamidine isethionate. Med Trop (Mars). 2003;63:35–44
  77. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg. 2005;72:133–137
  78. Brown M, Noursadeghi M, Boyle J, Davidson RN. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203–205
  79. Wortmann GW, Fraser SL, Aronson NE, et al. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis. 1998;26:1006–1007
  80. Requena JM, Iborra S, Carrion J, Alonso C, Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther. 2004;4:1505–1517
  81. Tuck JJH, Green AD, Roberts KI. A malaria outbreak following a British military deployment to Sierra Leone. J Infect. 2003;47:225–230

PII: S0738-081X(06)00071-X

doi: 10.1016/j.clindermatol.2006.05.008

Clinics in Dermatology
Volume 25, Issue 2 , Pages 203-211 , March 2007

Article Tools

* Image Usage & Resolution